Literature DB >> 6391747

Insulin resistance in cirrhosis: evidence for a post-receptor defect.

J Proietto, A Nankervis, P Aitken, F J Dudley, G Caruso, F P Alford.   

Abstract

Receptor and post-receptor abnormalities of insulin action and their possible role in the insulin resistance of cirrhosis were examined in eight biopsy-proven cirrhotic subjects and eight age-weight matched healthy volunteers. To this end, oral glucose tolerance tests (OGTT), insulin dose response curves and insulin binding to circulating monocytes were determined for each subject. The dose-response curves for the cirrhotic subjects were significantly shifted to the right compared to the control subjects, indicating the presence of insulin insensitivity (ED50 223 +/- 30 versus 64 +/- 8 mU/l respectively; P less than 0.001). The magnitude of the right shift of the insulin-dose response curves correlated significantly (P less than 0.001) with the OGTT 2 h insulin levels (r = 0.74) and the insulin areas under the OGTT curves (r = 0.86). In contrast, insulin responsiveness was marginally elevated in the cirrhotic group (maximal glucose disposal 680 +/- 47 versus 574 +/- 21 ml/m2/min; P less than 0.05). Insulin binding to circulating monocytes was normal in the cirrhotic subjects. It is concluded that the insulin resistance of cirrhosis is due to a post-receptor defect in insulin action which reduces insulin sensitivity but not insulin responsiveness.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391747     DOI: 10.1111/j.1365-2265.1984.tb01410.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Defective glucose utilization in patients with functioning beta-cell tumors persists after tumor excision.

Authors:  G S McGee; M M Kulaylat; N N Abumrad
Journal:  Ann Surg       Date:  1987-10       Impact factor: 12.969

Review 2.  Insulin receptors and the clinician.

Authors:  R Taylor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

3.  Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis.

Authors:  N Tanabe; M Ishii; Y Sato; T Akahane; N Kobayashi; H Gama; T Iwasaki; T Toyota
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

4.  Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis.

Authors:  A S Petrides; W Passlack; H Reinauer; W Stremmel; G Strohmeyer
Journal:  Klin Wochenschr       Date:  1987-09-15

5.  In vivo insulin action in hepatocellular and cholestatic liver cirrhosis.

Authors:  N Barzilai; P Cohen; E Karnieli; R Enat; O Epstein; J Owen; N McIntyre
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

6.  The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients.

Authors:  V De Sanctis; G D'Ascola; B Wonke
Journal:  Postgrad Med J       Date:  1986-09       Impact factor: 2.401

7.  Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis.

Authors:  G Marchesini; G P Bianchi; G Forlani; A G Rusticali; D Patrono; M Capelli; M Zoli; P Vannini; E Pisi
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

8.  Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis.

Authors:  A S Petrides; L C Groop; C A Riely; R A DeFronzo
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

9.  Hyperinsulinaemia and insulin insensitivity: studies in subjects with insulinoma.

Authors:  A Nankervis; J Proietto; P Aitken; F Alford
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

10.  Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease.

Authors:  Shoko Kuriyama; Yoshiyuki Miwa; Hideki Fukushima; Hironori Nakamura; Katsuhisa Toda; Makoto Shiraki; Masahito Nagaki; Mayumi Yamamoto; Eiichi Tomita; Hisataka Moriwaki
Journal:  J Clin Biochem Nutr       Date:  2007-03       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.